<DOC>
	<DOCNO>NCT02293408</DOCNO>
	<brief_summary>The objective study describe clinical biochemical characteristic course disease progression patient MPS IIIB</brief_summary>
	<brief_title>Natural History Study Characterise Course Disease Progression Patients With Mucopolysaccharidosis Type IIIB</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>A patient must meet follow inclusion criterion eligible study : 1 . The patient definitive diagnosis MPS IIIB , determine either follow : 1 . Documented deficiency alphaNacetylglucosaminidase ( NAGLU ) enzyme activity 2 . Documented functionallyrelevant mutation allele NAGLU gene . 2 . The patient least 1 year age ( biological age ) . 3 . The patient patient 's parent provide informed consent . 4 . The patient willing able comply protocol requirement extent may expect patient cognitive impairment . In addition eligibility criterion , patient must meet follow criterion Component 2 : 1 . The patient meet criterion criterion b . . The patient consider risk rapid disease progression base least one follow criterion : . The patient document mutation NAGLU gene report link rapid disease progression ( e.g. , disease onset 6 year age ) , ii . The patient sibling , first seconddegree relative rapidly progress MPS IIIB ( e.g. , disease onset 6 year age ) . b . The patient disease onset prior 6 year age ( biological age ) , define : i. cognitive delay evaluate Bayley Scales infant development , Third edition ( BSIDIII ) Kaufman Assessment Battery child , second edition ( KABCII ) , ii . language delay , plateauing regression language skill determine investigator ( eg . patient us isolated word , associate word two word combination , sentence , poor reduce language and/or difficult understand . 2 . The patient age equivalent â‰¥1 year Vineland II . A patient meet follow exclusion criterion ineligible study : 1 . The patient visual hearing impairment sufficient preclude cooperation neurodevelopmental testing . 2 . The patient history poorlycontrolled seizure disorder . 3 . The patient currently receive medication , Investigator 's opinion , would likely substantially confound interpretation result ( eg . patient current dose psychotropic medication le 3 month ) . 4 . The patient receive newly increase dose melatonin ( eg . le 3 month current dose ) . 5 . The patient previously receive investigational therapy MPS IIIB ( exception high dose Genistein &gt; 150mg/kg/day , require minimum 3 month washout enter study ) hematopoietic stem cell transplant ( HSCT ) . 6 . The patient prior ongoing medial condition may present safety risk , interfere study compliance , confound data interpretation .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>MPS IIIB</keyword>
	<keyword>Mucopolysaccharidosis</keyword>
	<keyword>Mucopolysaccharidosis type IIIB</keyword>
	<keyword>Sanfilippo Syndrome</keyword>
</DOC>